Search Results: Treatment + Breast Cancer (22 results)
A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Gene Abnormalities in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Comparing the Safety and Effectiveness of a New Hormonal Therapy in Patients with HER2-Negative, ER-Positive Early Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/254/comparing-the-safety-and-effectiveness-of-secondary-treatments-in-patients-with-her2-negative-early-breast-cancer
Treatment
Treatment study for people with early-stage breast cancer
This study is comparing safety and effectiveness of a new drug called giredestrant compared to standard hormone therapy in people with early-stage, ER-positive breast cancer.
Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers
https://www.facingourrisk.org/research-clinical-trials/study/232/testing-a-targeted-therapy-in-combination-with-chemotherapy-for-advanced-solid-tumors
Treatment
Treatment study for people with advanced cancers
This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
https://www.facingourrisk.org/research-clinical-trials/study/183/parp-inhibitor-niraparib-in-patients-with-inherited-or-tumor-palb2-mutations-in-advanced-solid-tumors-pavo
Treatment
Any advanced or metastatic solid tumor except ovarian or prostate
PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHK1, CHK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations
https://www.facingourrisk.org/research-clinical-trials/study/249/study-of-two-drugs-in-er-andor-pr-cancers-with-pi3k-andor-pten-tumor-or-inherited-mutations
Treatment
People with advanced breast or endometrial or ovarian cancer
This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER-positive and/or PR-positive cancers. People with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible.
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only.
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)
https://www.facingourrisk.org/research-clinical-trials/study/179/targeted-therapy-rp-3500-alone-or-in-combination-with-talazoparib-or-gemcitabine-in-advanced-solid-tumors-with-dna-damage-repair-mutations-tresr-study
Treatment
Advanced solid tumors
This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
https://www.facingourrisk.org/research-clinical-trials/study/155/atr-inhibitor-plus-niraparib-study-in-advanced-solid-tumors-and-ovarian-cancer
Treatment
Advanced ovarian cancer or other solid tumors
This study will look at how well how well people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib.
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/178/a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations
https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations
Treatment
Advanced solid tumors
This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.
HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/147/olaparib-palbociclib-and-fulvestrant-for-brca-associated-erpr-positive-her2-negative-metastatic-breast-cancer
Treatment
The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
https://www.facingourrisk.org/research-clinical-trials/study/68/olaparib-expanded-treating-metastatic-breast-cancer-in-people-without-gbrca-mutations
Treatment
Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer. Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. Currently the study is only recruiting people with an inherited PALB2 mutation or people who test negative for an inherited mutation in BRCA1 or BRCA2 but have an acquired (somatic) BRCA1 or BRCA2 mutation found on tumor testing.
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Treatment
This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for germline BRCA1/2 carriers) is effective in this population.
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Treatment
Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit the E-Reach registration page.
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial
https://www.facingourrisk.org/research-clinical-trials/study/56/radcomp-a-study-at-the-heart-of-breast-cancer-treatment
Treatment
The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.
We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer
474 results
Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://classic.clinicaltrials.gov/show/NCT05464667)
RAD 1802: Pilot Trial of Dose Adapted Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT ID: NCT03643861 (https://classic.clinicaltrials.gov/show/NCT03643861)
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT ID: NCT05528133 (https://classic.clinicaltrials.gov/show/NCT05528133)
Study of Stereotactic Radiotherapy for Breast Cancer
NCT ID: NCT03043794 (https://classic.clinicaltrials.gov/show/NCT03043794)
Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT ID: NCT02958774 (https://classic.clinicaltrials.gov/show/NCT02958774)
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://classic.clinicaltrials.gov/show/NCT04990921)
SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://classic.clinicaltrials.gov/show/NCT04360330)
Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
NCT ID: NCT05436808 (https://classic.clinicaltrials.gov/show/NCT05436808)
Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
NCT ID: NCT05472792 (https://classic.clinicaltrials.gov/show/NCT05472792)
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT ID: NCT03460067 (https://classic.clinicaltrials.gov/show/NCT03460067)
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT ID: NCT04454528 (https://classic.clinicaltrials.gov/show/NCT04454528)
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
NCT ID: NCT05591547 (https://classic.clinicaltrials.gov/show/NCT05591547)
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT ID: NCT04648904 (https://classic.clinicaltrials.gov/show/NCT04648904)
A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer
NCT ID: NCT04040569 (https://classic.clinicaltrials.gov/show/NCT04040569)
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
NCT ID: NCT03345420 (https://classic.clinicaltrials.gov/show/NCT03345420)
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT ID: NCT03945721 (https://classic.clinicaltrials.gov/show/NCT03945721)
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
NCT ID: NCT04849871 (https://classic.clinicaltrials.gov/show/NCT04849871)
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://classic.clinicaltrials.gov/show/NCT04923542)
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
NCT ID: NCT04965688 (https://classic.clinicaltrials.gov/show/NCT04965688)
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT ID: NCT02977468 (https://classic.clinicaltrials.gov/show/NCT02977468)
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://classic.clinicaltrials.gov/show/NCT04234386)
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT ID: NCT04837209 (https://classic.clinicaltrials.gov/show/NCT04837209)
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
NCT ID: NCT05774678 (https://classic.clinicaltrials.gov/show/NCT05774678)
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation
NCT ID: NCT05731791 (https://classic.clinicaltrials.gov/show/NCT05731791)
Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://classic.clinicaltrials.gov/show/NCT03909282)
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://classic.clinicaltrials.gov/show/NCT05288777)
Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients
NCT ID: NCT03981718 (https://classic.clinicaltrials.gov/show/NCT03981718)
Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer
NCT ID: NCT04443413 (https://classic.clinicaltrials.gov/show/NCT04443413)
Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT ID: NCT03789097 (https://classic.clinicaltrials.gov/show/NCT03789097)
Intraoperative Use of ClearEdge Device in Breast Conserving Surgery
NCT ID: NCT05456373 (https://classic.clinicaltrials.gov/show/NCT05456373)
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT ID: NCT01245712 (https://classic.clinicaltrials.gov/show/NCT01245712)
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT ID: NCT05289466 (https://classic.clinicaltrials.gov/show/NCT05289466)
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://classic.clinicaltrials.gov/show/NCT05245812)
SABR-CaRe in Early Stage Breast Cancer
NCT ID: NCT04959474 (https://classic.clinicaltrials.gov/show/NCT04959474)
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT ID: NCT05340673 (https://classic.clinicaltrials.gov/show/NCT05340673)
Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations
NCT ID: NCT02917421 (https://classic.clinicaltrials.gov/show/NCT02917421)
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
NCT ID: NCT05269160 (https://classic.clinicaltrials.gov/show/NCT05269160)
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
NCT ID: NCT04175210 (https://classic.clinicaltrials.gov/show/NCT04175210)
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://classic.clinicaltrials.gov/show/NCT02926729)
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT ID: NCT03979508 (https://classic.clinicaltrials.gov/show/NCT03979508)
An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx System
NCT ID: NCT03561454 (https://classic.clinicaltrials.gov/show/NCT03561454)
Intraoperative Radiation Therapy (IORT) in DCIS
NCT ID: NCT03216421 (https://classic.clinicaltrials.gov/show/NCT03216421)
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
NCT ID: NCT02807597 (https://classic.clinicaltrials.gov/show/NCT02807597)
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://classic.clinicaltrials.gov/show/NCT05130801)
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT ID: NCT05710328 (https://classic.clinicaltrials.gov/show/NCT05710328)
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://classic.clinicaltrials.gov/show/NCT06006806)
Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy
NCT ID: NCT03768492 (https://classic.clinicaltrials.gov/show/NCT03768492)
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
NCT ID: NCT04272801 (https://classic.clinicaltrials.gov/show/NCT04272801)
Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery
NCT ID: NCT04233385 (https://classic.clinicaltrials.gov/show/NCT04233385)
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT ID: NCT03796273 (https://classic.clinicaltrials.gov/show/NCT03796273)
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT ID: NCT01185132 (https://classic.clinicaltrials.gov/show/NCT01185132)
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT ID: NCT02927912 (https://classic.clinicaltrials.gov/show/NCT02927912)
Well-Being After Breast Cancer Surgery
NCT ID: NCT04225585 (https://classic.clinicaltrials.gov/show/NCT04225585)
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://classic.clinicaltrials.gov/show/NCT04563507)
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT ID: NCT05892068 (https://classic.clinicaltrials.gov/show/NCT05892068)
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT ID: NCT04371913 (https://classic.clinicaltrials.gov/show/NCT04371913)
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
NCT ID: NCT03546686 (https://classic.clinicaltrials.gov/show/NCT03546686)
An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction
NCT ID: NCT03990610 (https://classic.clinicaltrials.gov/show/NCT03990610)
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
NCT ID: NCT04815083 (https://classic.clinicaltrials.gov/show/NCT04815083)
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT ID: NCT03488693 (https://classic.clinicaltrials.gov/show/NCT03488693)
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT ID: NCT05705401 (https://classic.clinicaltrials.gov/show/NCT05705401)
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT ID: NCT05351424 (https://classic.clinicaltrials.gov/show/NCT05351424)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://classic.clinicaltrials.gov/show/NCT05422794)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://classic.clinicaltrials.gov/show/NCT05929768)
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT ID: NCT05504707 (https://classic.clinicaltrials.gov/show/NCT05504707)
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT ID: NCT04616248 (https://classic.clinicaltrials.gov/show/NCT04616248)
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT ID: NCT04993313 (https://classic.clinicaltrials.gov/show/NCT04993313)
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT ID: NCT03765983 (https://classic.clinicaltrials.gov/show/NCT03765983)
UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization
NCT ID: NCT05178927 (https://classic.clinicaltrials.gov/show/NCT05178927)
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT ID: NCT01766297 (https://classic.clinicaltrials.gov/show/NCT01766297)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT ID: NCT04852887 (https://classic.clinicaltrials.gov/show/NCT04852887)
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT ID: NCT04270149 (https://classic.clinicaltrials.gov/show/NCT04270149)
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT ID: NCT04020575 (https://classic.clinicaltrials.gov/show/NCT04020575)
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT ID: NCT04588545 (https://classic.clinicaltrials.gov/show/NCT04588545)
Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
NCT ID: NCT02564848 (https://classic.clinicaltrials.gov/show/NCT02564848)
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT ID: NCT05325632 (https://classic.clinicaltrials.gov/show/NCT05325632)
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT ID: NCT04427293 (https://classic.clinicaltrials.gov/show/NCT04427293)
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery
NCT ID: NCT01570998 (https://classic.clinicaltrials.gov/show/NCT01570998)
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://classic.clinicaltrials.gov/show/NCT05412225)
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05447910 (https://classic.clinicaltrials.gov/show/NCT05447910)
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://classic.clinicaltrials.gov/show/NCT05378464)
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://classic.clinicaltrials.gov/show/NCT04329065)
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT ID: NCT02760030 (https://classic.clinicaltrials.gov/show/NCT02760030)
CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT ID: NCT04368702 (https://classic.clinicaltrials.gov/show/NCT04368702)
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT ID: NCT04674306 (https://classic.clinicaltrials.gov/show/NCT04674306)
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
NCT ID: NCT05190770 (https://classic.clinicaltrials.gov/show/NCT05190770)
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
NCT ID: NCT05081492 (https://classic.clinicaltrials.gov/show/NCT05081492)
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
NCT ID: NCT05226663 (https://classic.clinicaltrials.gov/show/NCT05226663)
Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT ID: NCT04998682 (https://classic.clinicaltrials.gov/show/NCT04998682)
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT ID: NCT03598257 (https://classic.clinicaltrials.gov/show/NCT03598257)
Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer
NCT ID: NCT04149522 (https://classic.clinicaltrials.gov/show/NCT04149522)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://classic.clinicaltrials.gov/show/NCT04899908)
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://classic.clinicaltrials.gov/show/NCT04348747)
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
NCT ID: NCT04871516 (https://classic.clinicaltrials.gov/show/NCT04871516)
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://classic.clinicaltrials.gov/show/NCT03804944)
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT ID: NCT02912312 (https://classic.clinicaltrials.gov/show/NCT02912312)
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT ID: NCT04120246 (https://classic.clinicaltrials.gov/show/NCT04120246)
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://classic.clinicaltrials.gov/show/NCT04683679)
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://classic.clinicaltrials.gov/show/NCT04521764)
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
NCT ID: NCT04108858 (https://classic.clinicaltrials.gov/show/NCT04108858)
Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT ID: NCT02945579 (https://classic.clinicaltrials.gov/show/NCT02945579)
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
NCT ID: NCT02603341 (https://classic.clinicaltrials.gov/show/NCT02603341)
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT ID: NCT04443348 (https://classic.clinicaltrials.gov/show/NCT04443348)
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
NCT ID: NCT05457842 (https://classic.clinicaltrials.gov/show/NCT05457842)
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
NCT ID: NCT05142358 (https://classic.clinicaltrials.gov/show/NCT05142358)
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://classic.clinicaltrials.gov/show/NCT05534438)
Impact of Topical Tranexamic Acid in Breast Reconstruction
NCT ID: NCT05807074 (https://classic.clinicaltrials.gov/show/NCT05807074)
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT ID: NCT04009044 (https://classic.clinicaltrials.gov/show/NCT04009044)
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
NCT ID: NCT04946864 (https://classic.clinicaltrials.gov/show/NCT04946864)
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
NCT ID: NCT04879849 (https://classic.clinicaltrials.gov/show/NCT04879849)
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT ID: NCT05455658 (https://classic.clinicaltrials.gov/show/NCT05455658)
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
NCT ID: NCT05549505 (https://classic.clinicaltrials.gov/show/NCT05549505)
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
NCT ID: NCT04440982 (https://classic.clinicaltrials.gov/show/NCT04440982)
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://classic.clinicaltrials.gov/show/NCT04389281)
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://classic.clinicaltrials.gov/show/NCT05464082)
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT ID: NCT04084730 (https://classic.clinicaltrials.gov/show/NCT04084730)
Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
NCT ID: NCT04989504 (https://classic.clinicaltrials.gov/show/NCT04989504)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT ID: NCT05098210 (https://classic.clinicaltrials.gov/show/NCT05098210)
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT ID: NCT05376878 (https://classic.clinicaltrials.gov/show/NCT05376878)
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT ID: NCT05809752 (https://classic.clinicaltrials.gov/show/NCT05809752)
Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
NCT ID: NCT04568616 (https://classic.clinicaltrials.gov/show/NCT04568616)
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://classic.clinicaltrials.gov/show/NCT03694756)
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT ID: NCT04266249 (https://classic.clinicaltrials.gov/show/NCT04266249)
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT ID: NCT03213041 (https://classic.clinicaltrials.gov/show/NCT03213041)
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage
NCT ID: NCT05554211 (https://classic.clinicaltrials.gov/show/NCT05554211)
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT ID: NCT04003038 (https://classic.clinicaltrials.gov/show/NCT04003038)
Perioperative Mindfulness Proposal
NCT ID: NCT04049214 (https://classic.clinicaltrials.gov/show/NCT04049214)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://classic.clinicaltrials.gov/show/NCT04553770)
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
NCT ID: NCT04534010 (https://classic.clinicaltrials.gov/show/NCT04534010)
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://classic.clinicaltrials.gov/show/NCT05677802)
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT ID: NCT04606030 (https://classic.clinicaltrials.gov/show/NCT04606030)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
NCT ID: NCT05633654 (https://classic.clinicaltrials.gov/show/NCT05633654)
Refining Local-Regional Therapy for IBC
NCT ID: NCT04636710 (https://classic.clinicaltrials.gov/show/NCT04636710)
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT ID: NCT03808337 (https://classic.clinicaltrials.gov/show/NCT03808337)
Axillary Lymph Node Tattoo Marking Study
NCT ID: NCT04947917 (https://classic.clinicaltrials.gov/show/NCT04947917)
Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors
NCT ID: NCT05595499 (https://classic.clinicaltrials.gov/show/NCT05595499)
TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://classic.clinicaltrials.gov/show/NCT05795101)
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT ID: NCT04445844 (https://classic.clinicaltrials.gov/show/NCT04445844)
Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT ID: NCT03596073 (https://classic.clinicaltrials.gov/show/NCT03596073)
Mastectomy Flap Temperature Study
NCT ID: NCT05395936 (https://classic.clinicaltrials.gov/show/NCT05395936)
Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
NCT ID: NCT04535323 (https://classic.clinicaltrials.gov/show/NCT04535323)
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT ID: NCT05219695 (https://classic.clinicaltrials.gov/show/NCT05219695)
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT ID: NCT05568472 (https://classic.clinicaltrials.gov/show/NCT05568472)
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT ID: NCT03572374 (https://classic.clinicaltrials.gov/show/NCT03572374)
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT ID: NCT05074290 (https://classic.clinicaltrials.gov/show/NCT05074290)
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT ID: NCT03820141 (https://classic.clinicaltrials.gov/show/NCT03820141)
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT ID: NCT05954143 (https://classic.clinicaltrials.gov/show/NCT05954143)
3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer
NCT ID: NCT05704283 (https://classic.clinicaltrials.gov/show/NCT05704283)
Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT ID: NCT05023967 (https://classic.clinicaltrials.gov/show/NCT05023967)
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://classic.clinicaltrials.gov/show/NCT05319873)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://classic.clinicaltrials.gov/show/NCT05673200)
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
NCT ID: NCT03696030 (https://classic.clinicaltrials.gov/show/NCT03696030)
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03742102 (https://classic.clinicaltrials.gov/show/NCT03742102)
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT ID: NCT05557877 (https://classic.clinicaltrials.gov/show/NCT05557877)
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT ID: NCT04197687 (https://classic.clinicaltrials.gov/show/NCT04197687)
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT ID: NCT04824027 (https://classic.clinicaltrials.gov/show/NCT04824027)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://classic.clinicaltrials.gov/show/NCT05313191)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://classic.clinicaltrials.gov/show/NCT05768139)
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT ID: NCT04784715 (https://classic.clinicaltrials.gov/show/NCT04784715)
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03801369 (https://classic.clinicaltrials.gov/show/NCT03801369)
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://classic.clinicaltrials.gov/show/NCT03796559)
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT ID: NCT03095352 (https://classic.clinicaltrials.gov/show/NCT03095352)
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT ID: NCT04711824 (https://classic.clinicaltrials.gov/show/NCT04711824)
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
NCT ID: NCT05113927 (https://classic.clinicaltrials.gov/show/NCT05113927)
FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer
NCT ID: NCT03179904 (https://classic.clinicaltrials.gov/show/NCT03179904)
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
NCT ID: NCT03535506 (https://classic.clinicaltrials.gov/show/NCT03535506)
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer
NCT ID: NCT04397185 (https://classic.clinicaltrials.gov/show/NCT04397185)
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT ID: NCT03351348 (https://classic.clinicaltrials.gov/show/NCT03351348)
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT ID: NCT04647916 (https://classic.clinicaltrials.gov/show/NCT04647916)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT ID: NCT04514484 (https://classic.clinicaltrials.gov/show/NCT04514484)
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
NCT ID: NCT03747120 (https://classic.clinicaltrials.gov/show/NCT03747120)
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://classic.clinicaltrials.gov/show/NCT05190978)
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://classic.clinicaltrials.gov/show/NCT04677816)
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
NCT ID: NCT04072393 (https://classic.clinicaltrials.gov/show/NCT04072393)
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT ID: NCT03321045 (https://classic.clinicaltrials.gov/show/NCT03321045)
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://classic.clinicaltrials.gov/show/NCT05291507)
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://classic.clinicaltrials.gov/show/NCT04768426)
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT ID: NCT03272334 (https://classic.clinicaltrials.gov/show/NCT03272334)
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://classic.clinicaltrials.gov/show/NCT05837767)
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT ID: NCT04965064 (https://classic.clinicaltrials.gov/show/NCT04965064)
Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT ID: NCT05744557 (https://classic.clinicaltrials.gov/show/NCT05744557)
Focused Ultrasound and Gemcitabine in Breast Cancer
NCT ID: NCT04796220 (https://classic.clinicaltrials.gov/show/NCT04796220)
Testing a New Imaging Agent to Identify Cancer
NCT ID: NCT04692831 (https://classic.clinicaltrials.gov/show/NCT04692831)
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT ID: NCT05770531 (https://classic.clinicaltrials.gov/show/NCT05770531)
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT ID: NCT05629585 (https://classic.clinicaltrials.gov/show/NCT05629585)
Study of CRX100 in Patients With Advanced Solid Tumors
NCT ID: NCT04282044 (https://classic.clinicaltrials.gov/show/NCT04282044)
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT ID: NCT05146297 (https://classic.clinicaltrials.gov/show/NCT05146297)
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
NCT ID: NCT03739931 (https://classic.clinicaltrials.gov/show/NCT03739931)
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT ID: NCT05720039 (https://classic.clinicaltrials.gov/show/NCT05720039)
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
NCT ID: NCT03960463 (https://classic.clinicaltrials.gov/show/NCT03960463)
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT ID: NCT03504488 (https://classic.clinicaltrials.gov/show/NCT03504488)
Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT05076760 (https://classic.clinicaltrials.gov/show/NCT05076760)
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT ID: NCT04147494 (https://classic.clinicaltrials.gov/show/NCT04147494)
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT ID: NCT04265872 (https://classic.clinicaltrials.gov/show/NCT04265872)
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
NCT ID: NCT05203445 (https://classic.clinicaltrials.gov/show/NCT05203445)
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
NCT ID: NCT04090398 (https://classic.clinicaltrials.gov/show/NCT04090398)
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
NCT ID: NCT05747794 (https://classic.clinicaltrials.gov/show/NCT05747794)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://classic.clinicaltrials.gov/show/NCT03428802)
Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients
NCT ID: NCT03303846 (https://classic.clinicaltrials.gov/show/NCT03303846)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT ID: NCT05232916 (https://classic.clinicaltrials.gov/show/NCT05232916)
RAPA-201 Therapy of Solid Tumors
NCT ID: NCT05144698 (https://classic.clinicaltrials.gov/show/NCT05144698)
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT ID: NCT04144023 (https://classic.clinicaltrials.gov/show/NCT04144023)
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
NCT ID: NCT05807126 (https://classic.clinicaltrials.gov/show/NCT05807126)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://classic.clinicaltrials.gov/show/NCT04673448)
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
NCT ID: NCT05703269 (https://classic.clinicaltrials.gov/show/NCT05703269)
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT ID: NCT05633979 (https://classic.clinicaltrials.gov/show/NCT05633979)
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT ID: NCT04756765 (https://classic.clinicaltrials.gov/show/NCT04756765)
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
NCT ID: NCT04294628 (https://classic.clinicaltrials.gov/show/NCT04294628)
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
NCT ID: NCT04650256 (https://classic.clinicaltrials.gov/show/NCT04650256)
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
NCT ID: NCT05694364 (https://classic.clinicaltrials.gov/show/NCT05694364)
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://classic.clinicaltrials.gov/show/NCT04891068)
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://classic.clinicaltrials.gov/show/NCT03449238)
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT ID: NCT03562637 (https://classic.clinicaltrials.gov/show/NCT03562637)
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://classic.clinicaltrials.gov/show/NCT05693766)
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT ID: NCT04478279 (https://classic.clinicaltrials.gov/show/NCT04478279)
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
NCT ID: NCT04549571 (https://classic.clinicaltrials.gov/show/NCT04549571)
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT ID: NCT05069038 (https://classic.clinicaltrials.gov/show/NCT05069038)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://classic.clinicaltrials.gov/show/NCT05269381)
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://classic.clinicaltrials.gov/show/NCT03606967)
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://classic.clinicaltrials.gov/show/NCT04315233)
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
NCT ID: NCT03075072 (https://classic.clinicaltrials.gov/show/NCT03075072)
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NCT ID: NCT04588246 (https://classic.clinicaltrials.gov/show/NCT04588246)
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
NCT ID: NCT05545150 (https://classic.clinicaltrials.gov/show/NCT05545150)
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT ID: NCT05453825 (https://classic.clinicaltrials.gov/show/NCT05453825)
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
NCT ID: NCT04187898 (https://classic.clinicaltrials.gov/show/NCT04187898)
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
NCT ID: NCT05163223 (https://classic.clinicaltrials.gov/show/NCT05163223)
Scalp Cooling in MBC
NCT ID: NCT04986579 (https://classic.clinicaltrials.gov/show/NCT04986579)
Postoperative Opt-In Narcotics Treatment in Breast
NCT ID: NCT05078398 (https://classic.clinicaltrials.gov/show/NCT05078398)
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT ID: NCT04699630 (https://classic.clinicaltrials.gov/show/NCT04699630)
Combination Study of SV-BR-1-GM With Retifanlimab
NCT ID: NCT03328026 (https://classic.clinicaltrials.gov/show/NCT03328026)
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT ID: NCT03025035 (https://classic.clinicaltrials.gov/show/NCT03025035)
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
NCT ID: NCT05183126 (https://classic.clinicaltrials.gov/show/NCT05183126)
Microbiome and Association With Implant Infections
NCT ID: NCT05020574 (https://classic.clinicaltrials.gov/show/NCT05020574)
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://classic.clinicaltrials.gov/show/NCT04090567)
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT ID: NCT03742245 (https://classic.clinicaltrials.gov/show/NCT03742245)
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
NCT ID: NCT04243616 (https://classic.clinicaltrials.gov/show/NCT04243616)
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT ID: NCT04134884 (https://classic.clinicaltrials.gov/show/NCT04134884)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
NCT ID: NCT04669301 (https://classic.clinicaltrials.gov/show/NCT04669301)
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT ID: NCT05218044 (https://classic.clinicaltrials.gov/show/NCT05218044)
DNX-2440 for Resectable Colorectal Liver Metastasis
NCT ID: NCT04714983 (https://classic.clinicaltrials.gov/show/NCT04714983)
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT ID: NCT03740256 (https://classic.clinicaltrials.gov/show/NCT03740256)
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
NCT ID: NCT05924152 (https://classic.clinicaltrials.gov/show/NCT05924152)
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://classic.clinicaltrials.gov/show/NCT05607004)
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT ID: NCT05748834 (https://classic.clinicaltrials.gov/show/NCT05748834)
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT ID: NCT05826964 (https://classic.clinicaltrials.gov/show/NCT05826964)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://classic.clinicaltrials.gov/show/NCT04704661)
Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://classic.clinicaltrials.gov/show/NCT05092373)
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT ID: NCT05877599 (https://classic.clinicaltrials.gov/show/NCT05877599)
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT ID: NCT05675579 (https://classic.clinicaltrials.gov/show/NCT05675579)
A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
NCT ID: NCT05458674 (https://classic.clinicaltrials.gov/show/NCT05458674)
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://classic.clinicaltrials.gov/show/NCT05746897)
Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT ID: NCT05305924 (https://classic.clinicaltrials.gov/show/NCT05305924)
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
NCT ID: NCT05963984 (https://classic.clinicaltrials.gov/show/NCT05963984)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://classic.clinicaltrials.gov/show/NCT05812807)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://classic.clinicaltrials.gov/show/NCT04222413)
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT ID: NCT04703920 (https://classic.clinicaltrials.gov/show/NCT04703920)
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT ID: NCT03971409 (https://classic.clinicaltrials.gov/show/NCT03971409)
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT ID: NCT04457596 (https://classic.clinicaltrials.gov/show/NCT04457596)
Cancer Genetic Testing in Ethnic Populations
NCT ID: NCT04475640 (https://classic.clinicaltrials.gov/show/NCT04475640)
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT ID: NCT05035836 (https://classic.clinicaltrials.gov/show/NCT05035836)
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer
NCT ID: NCT05101564 (https://classic.clinicaltrials.gov/show/NCT05101564)
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
NCT ID: NCT04256941 (https://classic.clinicaltrials.gov/show/NCT04256941)
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
NCT ID: NCT02993159 (https://classic.clinicaltrials.gov/show/NCT02993159)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://classic.clinicaltrials.gov/show/NCT04644068)
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
NCT ID: NCT04246671 (https://classic.clinicaltrials.gov/show/NCT04246671)
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://classic.clinicaltrials.gov/show/NCT05524584)
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT ID: NCT04205903 (https://classic.clinicaltrials.gov/show/NCT04205903)
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT ID: NCT05150652 (https://classic.clinicaltrials.gov/show/NCT05150652)
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT ID: NCT03589339 (https://classic.clinicaltrials.gov/show/NCT03589339)
Non-Viral TCR Gene Therapy
NCT ID: NCT04102436 (https://classic.clinicaltrials.gov/show/NCT04102436)
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT ID: NCT05095207 (https://classic.clinicaltrials.gov/show/NCT05095207)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://classic.clinicaltrials.gov/show/NCT02830724)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT ID: NCT04895358 (https://classic.clinicaltrials.gov/show/NCT04895358)
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://classic.clinicaltrials.gov/show/NCT04174352)
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://classic.clinicaltrials.gov/show/NCT06042569)
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://classic.clinicaltrials.gov/show/NCT05020860)
RAGE Inhibition to Decrease Therapy Cardiotoxicity in Women With Early Breast Cancer
NCT ID: NCT05256745 (https://classic.clinicaltrials.gov/show/NCT05256745)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://classic.clinicaltrials.gov/show/NCT04722692)
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT ID: NCT05274451 (https://classic.clinicaltrials.gov/show/NCT05274451)
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT ID: NCT04711252 (https://classic.clinicaltrials.gov/show/NCT04711252)
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT ID: NCT03435952 (https://classic.clinicaltrials.gov/show/NCT03435952)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
NCT ID: NCT05111561 (https://classic.clinicaltrials.gov/show/NCT05111561)
GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT ID: NCT05180474 (https://classic.clinicaltrials.gov/show/NCT05180474)
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT ID: NCT02476786 (https://classic.clinicaltrials.gov/show/NCT02476786)
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
NCT ID: NCT03685331 (https://classic.clinicaltrials.gov/show/NCT03685331)
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
NCT ID: NCT05198843 (https://classic.clinicaltrials.gov/show/NCT05198843)
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT ID: NCT04660929 (https://classic.clinicaltrials.gov/show/NCT04660929)
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://classic.clinicaltrials.gov/show/NCT03990896)
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
NCT ID: NCT03934905 (https://classic.clinicaltrials.gov/show/NCT03934905)
Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer
NCT ID: NCT04345913 (https://classic.clinicaltrials.gov/show/NCT04345913)
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://classic.clinicaltrials.gov/show/NCT03671044)
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT ID: NCT05585034 (https://classic.clinicaltrials.gov/show/NCT05585034)
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT ID: NCT04787042 (https://classic.clinicaltrials.gov/show/NCT04787042)
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT ID: NCT04039230 (https://classic.clinicaltrials.gov/show/NCT04039230)
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT ID: NCT05655598 (https://classic.clinicaltrials.gov/show/NCT05655598)
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT03941730 (https://classic.clinicaltrials.gov/show/NCT03941730)
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT ID: NCT03604315 (https://classic.clinicaltrials.gov/show/NCT03604315)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT ID: NCT04491942 (https://classic.clinicaltrials.gov/show/NCT04491942)
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT ID: NCT05608252 (https://classic.clinicaltrials.gov/show/NCT05608252)
Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT ID: NCT04494945 (https://classic.clinicaltrials.gov/show/NCT04494945)
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT ID: NCT02276443 (https://classic.clinicaltrials.gov/show/NCT02276443)
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT ID: NCT04862585 (https://classic.clinicaltrials.gov/show/NCT04862585)
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
NCT ID: NCT04542135 (https://classic.clinicaltrials.gov/show/NCT04542135)
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT ID: NCT02095184 (https://classic.clinicaltrials.gov/show/NCT02095184)
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT ID: NCT05230810 (https://classic.clinicaltrials.gov/show/NCT05230810)
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
NCT ID: NCT04442126 (https://classic.clinicaltrials.gov/show/NCT04442126)
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT ID: NCT04614194 (https://classic.clinicaltrials.gov/show/NCT04614194)
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers
NCT ID: NCT04886531 (https://classic.clinicaltrials.gov/show/NCT04886531)
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT ID: NCT02422641 (https://classic.clinicaltrials.gov/show/NCT02422641)
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT ID: NCT05251714 (https://classic.clinicaltrials.gov/show/NCT05251714)
Breast Mesh Used in Two-staged Breast Reconstruction
NCT ID: NCT04967976 (https://classic.clinicaltrials.gov/show/NCT04967976)
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT ID: NCT04762979 (https://classic.clinicaltrials.gov/show/NCT04762979)
The PROMISE Study: Duavee in Women With DCIS
NCT ID: NCT02694809 (https://classic.clinicaltrials.gov/show/NCT02694809)
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID: NCT05576077 (https://classic.clinicaltrials.gov/show/NCT05576077)
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
NCT ID: NCT04577963 (https://classic.clinicaltrials.gov/show/NCT04577963)
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT ID: NCT03752398 (https://classic.clinicaltrials.gov/show/NCT03752398)
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT ID: NCT05700669 (https://classic.clinicaltrials.gov/show/NCT05700669)
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
NCT ID: NCT03917381 (https://classic.clinicaltrials.gov/show/NCT03917381)
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
NCT ID: NCT02484404 (https://classic.clinicaltrials.gov/show/NCT02484404)
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
NCT ID: NCT02872025 (https://classic.clinicaltrials.gov/show/NCT02872025)
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT04072952 (https://classic.clinicaltrials.gov/show/NCT04072952)
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
NCT ID: NCT05498155 (https://classic.clinicaltrials.gov/show/NCT05498155)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://classic.clinicaltrials.gov/show/NCT05894239)
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT ID: NCT05868226 (https://classic.clinicaltrials.gov/show/NCT05868226)
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT ID: NCT05132582 (https://classic.clinicaltrials.gov/show/NCT05132582)
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
NCT ID: NCT03368729 (https://classic.clinicaltrials.gov/show/NCT03368729)
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT ID: NCT03975647 (https://classic.clinicaltrials.gov/show/NCT03975647)
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
NCT ID: NCT05384119 (https://classic.clinicaltrials.gov/show/NCT05384119)
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
NCT ID: NCT03901469 (https://classic.clinicaltrials.gov/show/NCT03901469)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://classic.clinicaltrials.gov/show/NCT04550494)
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
NCT ID: NCT05261269 (https://classic.clinicaltrials.gov/show/NCT05261269)
Assessing the Immunogenicity of pING-hHER3FL
NCT ID: NCT03832855 (https://classic.clinicaltrials.gov/show/NCT03832855)
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT ID: NCT04841148 (https://classic.clinicaltrials.gov/show/NCT04841148)
Onvansertib + Paclitaxel In TNBC
NCT ID: NCT05383196 (https://classic.clinicaltrials.gov/show/NCT05383196)
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT ID: NCT04964934 (https://classic.clinicaltrials.gov/show/NCT04964934)
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT ID: NCT05259696 (https://classic.clinicaltrials.gov/show/NCT05259696)
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
NCT ID: NCT05029999 (https://classic.clinicaltrials.gov/show/NCT05029999)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT ID: NCT03412877 (https://classic.clinicaltrials.gov/show/NCT03412877)
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://classic.clinicaltrials.gov/show/NCT05464810)
Olaparib In Metastatic Breast Cancer
NCT ID: NCT03344965 (https://classic.clinicaltrials.gov/show/NCT03344965)
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT ID: NCT04584255 (https://classic.clinicaltrials.gov/show/NCT04584255)
Researching the Effect of Exercise on Cancer
NCT ID: NCT04589468 (https://classic.clinicaltrials.gov/show/NCT04589468)
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
NCT ID: NCT05383170 (https://classic.clinicaltrials.gov/show/NCT05383170)
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
NCT ID: NCT05451849 (https://classic.clinicaltrials.gov/show/NCT05451849)
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT ID: NCT03238495 (https://classic.clinicaltrials.gov/show/NCT03238495)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://classic.clinicaltrials.gov/show/NCT05564377)
A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer
NCT ID: NCT04916002 (https://classic.clinicaltrials.gov/show/NCT04916002)
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT ID: NCT01042379 (https://classic.clinicaltrials.gov/show/NCT01042379)
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
NCT ID: NCT05759949 (https://classic.clinicaltrials.gov/show/NCT05759949)
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT ID: NCT05374512 (https://classic.clinicaltrials.gov/show/NCT05374512)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://classic.clinicaltrials.gov/show/NCT03424005)
Ribociclib and Bicalutamide in AR+ TNBC
NCT ID: NCT03090165 (https://classic.clinicaltrials.gov/show/NCT03090165)
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT ID: NCT03412643 (https://classic.clinicaltrials.gov/show/NCT03412643)
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT ID: NCT05207709 (https://classic.clinicaltrials.gov/show/NCT05207709)
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT ID: NCT05307705 (https://classic.clinicaltrials.gov/show/NCT05307705)
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT ID: NCT04849364 (https://classic.clinicaltrials.gov/show/NCT04849364)
Sacituzumab Govitecan In TNBC
NCT ID: NCT04230109 (https://classic.clinicaltrials.gov/show/NCT04230109)
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT ID: NCT05864144 (https://classic.clinicaltrials.gov/show/NCT05864144)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://classic.clinicaltrials.gov/show/NCT05483491)
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT04958785 (https://classic.clinicaltrials.gov/show/NCT04958785)
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT ID: NCT04873362 (https://classic.clinicaltrials.gov/show/NCT04873362)
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
NCT ID: NCT04740918 (https://classic.clinicaltrials.gov/show/NCT04740918)
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT ID: NCT05840211 (https://classic.clinicaltrials.gov/show/NCT05840211)
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT ID: NCT03006172 (https://classic.clinicaltrials.gov/show/NCT03006172)
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT ID: NCT05296798 (https://classic.clinicaltrials.gov/show/NCT05296798)
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT ID: NCT04893109 (https://classic.clinicaltrials.gov/show/NCT04893109)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05382286 (https://classic.clinicaltrials.gov/show/NCT05382286)
A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05852691 (https://classic.clinicaltrials.gov/show/NCT05852691)
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT04567420 (https://classic.clinicaltrials.gov/show/NCT04567420)
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
NCT ID: NCT05966584 (https://classic.clinicaltrials.gov/show/NCT05966584)
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT ID: NCT05774951 (https://classic.clinicaltrials.gov/show/NCT05774951)
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT ID: NCT05501886 (https://classic.clinicaltrials.gov/show/NCT05501886)
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT ID: NCT04862663 (https://classic.clinicaltrials.gov/show/NCT04862663)
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
NCT ID: NCT05654623 (https://classic.clinicaltrials.gov/show/NCT05654623)
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05382299 (https://classic.clinicaltrials.gov/show/NCT05382299)
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT ID: NCT04622319 (https://classic.clinicaltrials.gov/show/NCT04622319)
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT ID: NCT04906395 (https://classic.clinicaltrials.gov/show/NCT04906395)
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT ID: NCT05646862 (https://classic.clinicaltrials.gov/show/NCT05646862)
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT04191499 (https://classic.clinicaltrials.gov/show/NCT04191499)
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
NCT ID: NCT05090358 (https://classic.clinicaltrials.gov/show/NCT05090358)
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT ID: NCT05323955 (https://classic.clinicaltrials.gov/show/NCT05323955)
Endocrine Response in Women With Invasive Lobular Breast Cancer
NCT ID: NCT02206984 (https://classic.clinicaltrials.gov/show/NCT02206984)
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
NCT ID: NCT05751668 (https://classic.clinicaltrials.gov/show/NCT05751668)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://classic.clinicaltrials.gov/show/NCT04802759)
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT ID: NCT05645380 (https://classic.clinicaltrials.gov/show/NCT05645380)
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT ID: NCT02264678 (https://classic.clinicaltrials.gov/show/NCT02264678)
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT ID: NCT03616587 (https://classic.clinicaltrials.gov/show/NCT03616587)
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT ID: NCT03746431 (https://classic.clinicaltrials.gov/show/NCT03746431)
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT ID: NCT05514054 (https://classic.clinicaltrials.gov/show/NCT05514054)
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT ID: NCT05306340 (https://classic.clinicaltrials.gov/show/NCT05306340)
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
NCT ID: NCT04669587 (https://classic.clinicaltrials.gov/show/NCT04669587)
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT ID: NCT04569747 (https://classic.clinicaltrials.gov/show/NCT04569747)
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://classic.clinicaltrials.gov/show/NCT05467891)
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial
NCT ID: NCT05554354 (https://classic.clinicaltrials.gov/show/NCT05554354)
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT ID: NCT05239143 (https://classic.clinicaltrials.gov/show/NCT05239143)
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT ID: NCT02488967 (https://classic.clinicaltrials.gov/show/NCT02488967)
MARGetuximab Or Trastuzumab (MARGOT)
NCT ID: NCT04425018 (https://classic.clinicaltrials.gov/show/NCT04425018)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT ID: NCT04468061 (https://classic.clinicaltrials.gov/show/NCT04468061)
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
NCT ID: NCT05065411 (https://classic.clinicaltrials.gov/show/NCT05065411)
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT ID: NCT05169567 (https://classic.clinicaltrials.gov/show/NCT05169567)
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://classic.clinicaltrials.gov/show/NCT04150042)
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT ID: NCT04975308 (https://classic.clinicaltrials.gov/show/NCT04975308)
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT ID: NCT05262400 (https://classic.clinicaltrials.gov/show/NCT05262400)
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT05765851 (https://classic.clinicaltrials.gov/show/NCT05765851)
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
NCT ID: NCT04448886 (https://classic.clinicaltrials.gov/show/NCT04448886)
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT ID: NCT05563220 (https://classic.clinicaltrials.gov/show/NCT05563220)
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT ID: NCT03367572 (https://classic.clinicaltrials.gov/show/NCT03367572)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://classic.clinicaltrials.gov/show/NCT05417594)
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
NCT ID: NCT05216432 (https://classic.clinicaltrials.gov/show/NCT05216432)
Roll-over Study to Allow Continued Access to Ribociclib
NCT ID: NCT05161195 (https://classic.clinicaltrials.gov/show/NCT05161195)
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
NCT ID: NCT05501769 (https://classic.clinicaltrials.gov/show/NCT05501769)
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
NCT ID: NCT05082610 (https://classic.clinicaltrials.gov/show/NCT05082610)
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
NCT ID: NCT03930680 (https://classic.clinicaltrials.gov/show/NCT03930680)
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT ID: NCT05891171 (https://classic.clinicaltrials.gov/show/NCT05891171)
A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
NCT ID: NCT05909397 (https://classic.clinicaltrials.gov/show/NCT05909397)
A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://classic.clinicaltrials.gov/show/NCT05150691)
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT ID: NCT04332653 (https://classic.clinicaltrials.gov/show/NCT04332653)
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT ID: NCT04180371 (https://classic.clinicaltrials.gov/show/NCT04180371)
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
NCT ID: NCT04991480 (https://classic.clinicaltrials.gov/show/NCT04991480)
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT ID: NCT05035407 (https://classic.clinicaltrials.gov/show/NCT05035407)
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT ID: NCT05000294 (https://classic.clinicaltrials.gov/show/NCT05000294)
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT ID: NCT03011684 (https://classic.clinicaltrials.gov/show/NCT03011684)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://classic.clinicaltrials.gov/show/NCT05277051)
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT ID: NCT04042701 (https://classic.clinicaltrials.gov/show/NCT04042701)
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT ID: NCT05007106 (https://classic.clinicaltrials.gov/show/NCT05007106)
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
NCT ID: NCT04726332 (https://classic.clinicaltrials.gov/show/NCT04726332)
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT ID: NCT04659603 (https://classic.clinicaltrials.gov/show/NCT04659603)
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT ID: NCT03845166 (https://classic.clinicaltrials.gov/show/NCT03845166)
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT ID: NCT05593094 (https://classic.clinicaltrials.gov/show/NCT05593094)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
NCT ID: NCT04234113 (https://classic.clinicaltrials.gov/show/NCT04234113)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://classic.clinicaltrials.gov/show/NCT04771520)
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT ID: NCT04278144 (https://classic.clinicaltrials.gov/show/NCT04278144)
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies
NCT ID: NCT04561362 (https://classic.clinicaltrials.gov/show/NCT04561362)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05252390 (https://classic.clinicaltrials.gov/show/NCT05252390)
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT ID: NCT05311618 (https://classic.clinicaltrials.gov/show/NCT05311618)
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://classic.clinicaltrials.gov/show/NCT05887492)
PF-07104091 as a Single Agent and in Combination Therapy
NCT ID: NCT04553133 (https://classic.clinicaltrials.gov/show/NCT04553133)
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
NCT ID: NCT04570956 (https://classic.clinicaltrials.gov/show/NCT04570956)
Study of DF1001 in Patients With Advanced Solid Tumors
NCT ID: NCT04143711 (https://classic.clinicaltrials.gov/show/NCT04143711)
Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
NCT ID: NCT04742959 (https://classic.clinicaltrials.gov/show/NCT04742959)
A Study of SGN-B6A in Advanced Solid Tumors
NCT ID: NCT04389632 (https://classic.clinicaltrials.gov/show/NCT04389632)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://classic.clinicaltrials.gov/show/NCT04606446)
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT ID: NCT05708950 (https://classic.clinicaltrials.gov/show/NCT05708950)
(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://classic.clinicaltrials.gov/show/NCT05252416)
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
NCT ID: NCT04586335 (https://classic.clinicaltrials.gov/show/NCT04586335)
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT ID: NCT05650879 (https://classic.clinicaltrials.gov/show/NCT05650879)
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://classic.clinicaltrials.gov/show/NCT04925284)
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT ID: NCT05215574 (https://classic.clinicaltrials.gov/show/NCT05215574)
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT ID: NCT05169437 (https://classic.clinicaltrials.gov/show/NCT05169437)
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05070247 (https://classic.clinicaltrials.gov/show/NCT05070247)
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT04913337 (https://classic.clinicaltrials.gov/show/NCT04913337)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://classic.clinicaltrials.gov/show/NCT04585750)
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://classic.clinicaltrials.gov/show/NCT04140526)
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
NCT ID: NCT04254107 (https://classic.clinicaltrials.gov/show/NCT04254107)
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT ID: NCT04557449 (https://classic.clinicaltrials.gov/show/NCT04557449)
Study to Evaluate CCS1477 in Advanced Tumours
NCT ID: NCT03568656 (https://classic.clinicaltrials.gov/show/NCT03568656)
A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://classic.clinicaltrials.gov/show/NCT05107674)
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
NCT ID: NCT05898399 (https://classic.clinicaltrials.gov/show/NCT05898399)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://classic.clinicaltrials.gov/show/NCT05086692)
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://classic.clinicaltrials.gov/show/NCT04895709)
9-ING-41 in Patients With Advanced Cancers
NCT ID: NCT03678883 (https://classic.clinicaltrials.gov/show/NCT03678883)
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT ID: NCT05325866 (https://classic.clinicaltrials.gov/show/NCT05325866)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://classic.clinicaltrials.gov/show/NCT04300556)
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
NCT ID: NCT05716295 (https://classic.clinicaltrials.gov/show/NCT05716295)
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT ID: NCT04373564 (https://classic.clinicaltrials.gov/show/NCT04373564)
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT ID: NCT05537740 (https://classic.clinicaltrials.gov/show/NCT05537740)
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
NCT ID: NCT03674567 (https://classic.clinicaltrials.gov/show/NCT03674567)
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT ID: NCT05888831 (https://classic.clinicaltrials.gov/show/NCT05888831)
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT ID: NCT05500508 (https://classic.clinicaltrials.gov/show/NCT05500508)
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT ID: NCT04262466 (https://classic.clinicaltrials.gov/show/NCT04262466)
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT ID: NCT04794699 (https://classic.clinicaltrials.gov/show/NCT04794699)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.